| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $440,077 | 6 | 100 |
| Silverstein Christine Berni | director | 0 | $0 | 1 | $116,453 | $-116,453 |
| Seshadri Vishwas | Chief Executive Officer | 0 | $0 | 1 | $119,500 | $-119,500 |
| Alvino Mark | director | 0 | $0 | 4 | $204,124 | $-204,124 |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Over the last 12 months, insiders at Abeona Therapeutics Inc. have bought $0 and sold $440,077 worth of Abeona Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Abeona Therapeutics Inc. have bought $202,195 and sold $1.11M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 11,000 shares for transaction amount of $51,799 was made by Alland Leila (director) on 2024‑05‑16.
| 2025-05-16 | Sale | Alvino Mark | director | 8,000 0.0153% | $5.68 | $45,440 | +9.43% | |
| 2025-03-31 | Sale | Seshadri Vishwas | Chief Executive Officer | 25,000 0.0517% | $4.78 | $119,500 | +10.71% | |
| 2025-01-29 | Sale | Alvino Mark | director | 4,000 0.0092% | $5.38 | $21,520 | -2.94% | |
| 2025-01-21 | Sale | Alvino Mark | director | 4,000 0.0091% | $5.10 | $20,400 | +1.93% | |
| 2024-06-18 | Sale | Silverstein Christine Berni | director | 25,821 0.0635% | $4.51 | $116,453 | +22.36% | |
| 2024-06-18 | Sale | Alvino Mark | director | 25,890 0.0637% | $4.51 | $116,764 | +22.36% | |
| 2024-05-16 | Alland Leila | director | 11,000 0.0286% | $4.71 | $51,799 | +18.70% | ||
| 2024-04-26 | Charles Faith L. | director | 7,550 0.0265% | $3.28 | $24,764 | +62.73% | ||
| 2024-04-25 | Seshadri Vishwas | Chief Executive Officer | 10,000 0.0343% | $3.20 | $32,000 | +66.22% | ||
| 2024-04-25 | Vazzano Joseph Walter | Chief Financial Officer | 5,608 0.0189% | $3.14 | $17,609 | +66.22% | ||
| 2024-04-25 | O'Malley Brendan M. | SVP, General Counsel | 8,600 0.0299% | $3.24 | $27,864 | +66.22% | ||
| 2024-02-06 | Seshadri Vishwas | Chief Executive Officer | 20,000 0.0784% | $4.39 | $87,800 | +32.33% | ||
| 2024-01-17 | Sale | Alvino Mark | director | 7,084 0.0285% | $5.11 | $36,199 | +9.53% | |
| 2023-09-27 | Sale | Amoroso Michael | director | 5,508 0.022% | $3.91 | $21,542 | +21.97% | |
| 2023-09-27 | Sale | Silverstein Christine Berni | director | 6,330 0.0252% | $3.91 | $24,721 | +21.97% | |
| 2023-09-27 | Sale | Alland Leila | director | 7,246 0.0288% | $3.90 | $28,270 | +21.97% | |
| 2023-09-27 | Sale | Charles Faith L. | director | 8,330 0.0417% | $4.91 | $40,924 | +21.97% | |
| 2023-09-27 | Sale | Alvino Mark | director | 6,316 0.0252% | $3.91 | $24,724 | +21.97% | |
| 2023-09-27 | Seshadri Vishwas | Chief Executive Officer | 20,000 0.083% | $4.07 | $81,400 | +21.97% | ||
| 2023-09-20 | Sale | Amoroso Michael | director | 327 0.0014% | $3.90 | $1,275 | +25.79% |
| Seshadri Vishwas | Chief Executive Officer | 1355322 2.6494% | $8.7M | 3 | 1 | +40.17% |
| Alvino Mark | director | 92435 0.1807% | $593,432.70 | 0 | 9 | |
| Silverstein Christine Berni | director | 62063 0.1213% | $398,444.46 | 0 | 2 | |
| SCO CAPITAL PARTNERS LLC | 11079292 21.6576% | $71.13M | 0 | 11 | ||
| Ayer Capital Management, LP | 10 percent owner | 2413163 4.7172% | $15.49M | 0 | 4 | |
| CARR EDWARD | Chief Financial Officer | 400169 0.7822% | $2.57M | 0 | 4 | |
| Ahn Mark J | director | 343182 0.6708% | $2.2M | 2 | 0 | <0.0001% |
| Rouhandeh Steven H | 315042 0.6158% | $2.02M | 1 | 0 | +20.49% | |
| FEINBERG LARRY N | 10 percent owner | 296483 0.5796% | $1.9M | 5 | 11 | |
| Buono Stefano | director | 270000 0.5278% | $1.73M | 3 | 0 | <0.0001% |
| Vazzano Joseph Walter | Chief Financial Officer | 233868 0.4572% | $1.5M | 3 | 0 | +24.35% |
| O'Malley Brendan M. | SVP, General Counsel | 188718 0.3689% | $1.21M | 4 | 5 | +20.57% |
| GRAY KERRY P | President and CEO | 183340 0.3584% | $1.18M | 2 | 0 | |
| Amoroso Michael | director | 108957 0.213% | $699,503.94 | 0 | 7 | |
| Alland Leila | director | 82857 0.162% | $531,941.94 | 1 | 1 | +18.7% |
| MCDADE HERBERT H | director | 81007 0.1584% | $520,064.94 | 0 | 1 | |
| Howell Stephen B. | director | 79494 0.1554% | $510,351.48 | 1 | 0 | <0.0001% |
| Charles Faith L. | director | 78323 0.1531% | $502,833.66 | 1 | 1 | +62.73% |
| Jeffrey B Davis | director | 67858 0.1326% | $435,648.36 | 1 | 0 | +20.49% |
| NOWOTNIK DAVID P | Sr Vice President R&D | 62000 0.1212% | $398,040.00 | 1 | 0 | |
| Meakem John J | director | 45000 0.088% | $288,900.00 | 3 | 0 | |
| Van Duyne Richard B | director | 6000 0.0117% | $38,520.00 | 1 | 0 | <0.0001% |
| Wider Todd | director | 0 0% | $0 | 2 | 8 | <0.0001% |
| Mann Paul Elliot | director | 0 0% | $0 | 0 | 6 |
$21,575,910 | 89 | 3.57% | $336.92M | |
$69,130,029 | 69 | 25.63% | $318.32M | |
$109,415,500 | 33 | 18.13% | $292.92M | |
$18,554,304 | 31 | -11.72% | $348.89M | |
$73,500,193 | 28 | 42.95% | $312.74M | |
Abeona Therapeutics Inc. (ABEO) | $3,668,031 | 23 | 1.97% | $328.43M |
$14,865,077 | 18 | -28.56% | $296.11M | |
$49,750,490 | 17 | 37.19% | $305.79M | |
$1,037,470 | 13 | 78.00% | $344.43M | |
$65,355,913 | 13 | -3.42% | $298.09M | |
$81,667,942 | 12 | -57.54% | $355.89M | |
$19,659,196 | 11 | 21.81% | $351.41M | |
$133,369,382 | 10 | 5.02% | $347.58M | |
$1,580,951 | 9 | -14.18% | $347.65M | |
$4,706,376 | 8 | 42.30% | $345.54M | |
$157,484,277 | 8 | 28.67% | $319.59M | |
$335,001 | 6 | -23.71% | $307.68M | |
$15,652,720 | 6 | -4.77% | $324.54M | |
$8 | 2 | 28.83% | $356.61M |
| Increased Positions | 41 | +69.49% | 3M | +8.45% |
| Decreased Positions | 21 | -35.59% | 4M | -11.58% |
| New Positions | 15 | New | 911,692 | New |
| Sold Out Positions | 8 | Sold Out | 85,791 | Sold Out |
| Total Postitions | 79 | +33.9% | 30M | -3.13% |
| Adage Capital Partners Gp, L.L.C. | $25,599.00 | 7.96% | 3.9M | +652,366 | +20.07% | 2024-12-31 |
| Suvretta Capital Management, Llc | $24,177.00 | 7.52% | 3.69M | 0 | 0% | 2024-12-31 |
| Nantahala Capital Management, Llc | $23,152.00 | 7.2% | 3.53M | +96,577 | +2.81% | 2024-12-31 |
| Millennium Management Llc | $13,889.00 | 4.32% | 2.12M | -184,459 | -8.01% | 2024-12-31 |
| Western Standard Llc | $13,674.00 | 4.25% | 2.08M | +386,321 | +22.75% | 2024-12-31 |
| Vanguard Group Inc | $12,897.00 | 4.01% | 1.97M | -41,603 | -2.07% | 2024-12-31 |
| Vivo Capital, Llc | $12,088.00 | 3.76% | 1.84M | 0 | 0% | 2024-12-31 |
| Rosalind Advisors, Inc. | $11,843.00 | 3.68% | 1.81M | -26,610 | -1.45% | 2024-12-31 |
| Laurion Capital Management Lp | $8,571.00 | 2.67% | 1.31M | 0 | 0% | 2024-12-31 |
| 683 Capital Management, Llc | $5,195.00 | 1.62% | 791,845 | +116,845 | +17.31% | 2024-12-31 |